Cargando…

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

PURPOSE: To demonstrate the safety and feasibility of the Urocross Expander System (formerly branded as XFLO Expander System), an implantable nitinol tissue expander to trea t patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Men of 5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woo, Henry H., Huang, Chi-Ping, Huang, William J., Chang, Yi-Huei, Lien, Chi-Shun, Chkhotua, Archil, Elterman, Dean S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385491/ https://www.ncbi.nlm.nih.gov/pubmed/35641601 http://dx.doi.org/10.1038/s41391-022-00548-z

Ejemplares similares

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study
por: Zhang, Weiyu, et al.
Publicado: (2019)

Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
por: Cindolo, Luca, et al.
Publicado: (2015)

Making shared decisions with older men selecting treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH): a pilot randomized trial
por: Ngu, Haidee, et al.
Publicado: (2022)

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
por: Gacci, M., et al.
Publicado: (2013)

Current consensus and controversies on male LUTS/BPH (part one)
por: Foo, Keong Tatt
Publicado: (2017)

Current consensus and controversies on male LUTS/BPH (part two)
por: Foo, Keong Tatt
Publicado: (2018)

Moving beyond BPH – A contemporary update on male LUTS
por: Chapple, Christopher R.
Publicado: (2019)

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED
por: Sebastianelli, A., et al.
Publicado: (2020)

Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH)
por: Sciacqua, L. V., et al.
Publicado: (2023)

Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia and associated LUTS
por: Kanai, A.J., et al.
Publicado: (2023)

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH
por: Gupta, Saurabh
Publicado: (2014)

Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors
por: Kolontarev, Konstantin, et al.
Publicado: (2016)

Recent advances in managing benign prostatic hyperplasia: The Rezūm System
por: Guelce, Dominique, et al.
Publicado: (2018)

Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)
por: Cambio, Angelo J, et al.
Publicado: (2007)

What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
por: Foo, Keong Tatt
Publicado: (2019)

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH
por: Roehrborn, C G, et al.
Publicado: (2011)

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH
por: De Nunzio, Cosimo, et al.
Publicado: (2022)

Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo‐controlled study
por: Rosen, Raymond C., et al.
Publicado: (2018)

Clinical Implications of Residual Urine in Korean Benign Prostatic Hyperplasia (BPH) Patients: A Prognostic Factor for BPH-Related Clinical Events
por: Ko, Young Hwii, et al.
Publicado: (2010)

Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression
por: D’Agate, Salvatore, et al.
Publicado: (2020)

Bladder stone secondary to prostatic urethral lift (PUL) for benign prostatic hyperplasia (BPH)
por: Kang, JiHun
Publicado: (2021)

Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
por: Manohar, Chikka Moga Siddaiah, et al.
Publicado: (2017)

Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
por: Alcaraz, Antonio, et al.
Publicado: (2021)

LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations
por: De Nunzio, Cosimo, et al.
Publicado: (2021)

Early Experience with Laparoscopic Retropubic Simple Prostatectomy in Patients with Voluminous Benign Prostatic Hyperplasia (BPH)
por: Yun, Han Ki, et al.
Publicado: (2010)

Assessing the Influence of Benign Prostatic Hyperplasia (BPH) on Erectile Dysfunction (ED) among patients in Poland
por: Dutkiewicz, Sławomir, et al.
Publicado: (2012)

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network
por: Hellwege, Jacklyn N., et al.
Publicado: (2019)

Detection of Prostatic Inflammation From Peripheral Lymphocyte Count and Free/Total PSA Ratio in Men With LUTS/BPH
por: Liao, Xinyang, et al.
Publicado: (2020)

Relationship among diet habit and lower urinary tract symptoms and sexual function in outpatient-based males with LUTS/BPH: a multiregional and cross-sectional study in China
por: Chen, Yuke, et al.
Publicado: (2016)

AB201. Two birds with one stone: α-blocker therapy on LUTS/BPH in men concomitant with mild hypertension
por: Xiao, Hengjun, et al.
Publicado: (2016)

WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH
por: Kirschner-Hermanns, Ruth, et al.
Publicado: (2019)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands
por: Drake, Marcus J., et al.
Publicado: (2017)

Inflammatory Responses in a Benign Prostatic Hyperplasia Epithelial Cell Line (BPH-1) Infected with Trichomonas vaginalis
por: Kim, Sang-Su, et al.
Publicado: (2016)

Real‐world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain
por: María Molero, José, et al.
Publicado: (2020)

Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH)
por: Saponaro, Miriam, et al.
Publicado: (2020)

Therapeutic potential of pomegranate juice-derived nanovesicles in nude mouse benign prostatic hyperplasia (BPH) xenograft model
por: Sreekumar, Amritha, et al.
Publicado: (2023)

Correlation Analysis of Erectile Dysfunction with Lower Urinary Tract Symptoms (LUTS) Degree and Clinical Features in LUTS Patients
por: WANG, Lei, et al.
Publicado: (2018)

Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies
por: Elterman, Dean, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k5m074qrsgosn4p6en9m8s972i